

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Paediatric galenics: a challenge and an opportunity proposed by A.P.P.A.® Project for Developing Countries

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/152716> since

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Paediatric galenics: a challenge and an opportunity proposed by *A.P.P.A.*[®] Project for Developing Countries

Francesca Baratta

*Non-profit organization Aid Progress Pharmacist Agreement[®],
Turin, Italy*

*Department of Scienza e Tecnologia del Farmaco,
University of Turin, Italy*



Alma-Ata Declaration - 1978

*"... **the Primary Health Care**... forms an integral part both of the country's health system, of which it is the central function and main focus, and of the overall social and economic development of the community. It is the first level of contact... with the national health system, **bringing health care as close as possible to where people live and work, and constitutes the first element of a continuing health care service...**"*

TODAY?

2005



Problem to be addressed

Weak market control.

Inappropriate legal status of national medicine regulatory authorities to carry out their regulatory functions.

Inadequate legislation and regulations.

Weak quality control laboratories.

Inadequate regulation of clinical trials.

Inadequate import and export controls.


Existence of counterfeit products on national markets.

Local production firms non-compliant with GMP (ARVs, anti-malarial and anti-TB medicines).



2010

Assessment
of medicines regulatory systems
in sub-Saharan African countries
An overview of findings from 28 assessment reports




As a result, medicines regulation was not carried out to the full extent required to ensure the quality, efficacy and safety of medicines in African countries. The findings confirm the results of a 2004 questionnaire survey conducted by WHO in 38 African member states, which found that 90% of countries did not provide or enforce adequate regulatory functions



ACCESS TO HEALTH SERVICES: INEQUALITIES BETWEEN NORTH AND SOUTH OF THE WORLD

Countries with a critical shortage of health service providers
(doctors, nurses and midwives)



PROBLEMS RELATED TO THE LIFE STILE


«...water-borne diseases are not caused by lack of antibiotics but by **dirty water**, and by the political, social, and economic forces that fail to make clean water available to all; heart disease is caused not by a lack of coronary care units but by the **lives people lead**, which are shaped by the environments in which they live; obesity is not caused by moral failure on the part of individuals but by the excess availability of high-fat and high-sugar foods ...»

“Closing the gap in a generation: Health equity through action on the social determinants of health” – WHO Commission on Social Determinants of Health - 2008



Borana Singing wells, Kenya





Essential medicines are those that satisfy the priority health care needs of the population. They are selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness.

Essential medicines are intended to be available within the context of functioning health systems at all times in **adequate amounts**, in the **appropriate dosage forms**, with assured **quality** and adequate **information**, and at a **price** the individual and the community can afford.

BUT...



- More than **fifty percent of the population** in the Region **have no regular access to essential medicines.**
- **Medicine supply** and **regulatory systems** are weak
- **Financial** as well as **human resources** are inadequate to ensure delivery of pharmaceutical services and ensure access to essential medicines.
- Circulation of **poor quality medicines**, high medicine **prices**, unethical promotion and **irrational use** of medicines poses additional challenges.

COUNTERFEIT MEDICINES

A counterfeit medicine is one which is **deliberately and fraudulently mislabeled with respect to identity and/or source**. Counterfeiting can apply to both branded and generic products and counterfeit products may include products with the correct ingredients or with the wrong ingredients, without active ingredients, with insufficient active ingredients or with fake packaging.

WHO - General information on counterfeit medicines

“IMPERFECT” COUNTERFEITS

«these products contain the right components, with an incorrect concentration and/or formulation resulting in defective quality specifications. In the vast majority of cases, they are devoid of any therapeutic efficacy»



“CRIMINAL” COUNTERFEITS

«they are apparently similar to the original medicinal product, but do not contain any active ingredient and can even include harmful or toxic substances. They are usually sold at high prices and for the treatment of serious pathologies. Consequences for users of criminal counterfeits can be fatal»



COUNTERFIET MEDICINES IN DC: ANALYSIS OF THE PHENOMENON


**Analysis of
196 samples
of medicinal
products**




F.Baratta, A. Germano, P. Brusa

**Diffusion of counterfeit drugs in
developing Countries and stability
of galenics stored for months
under different conditions of
temperature and relative humidity**

Croat Med J. 2012; 53: 173-184



FINAL DISTRIBUTION OF THE SAMPLES





F.Baratta, A.
Germano, P. Brusa

**Diffusion of
counterfeit drugs
in developing
countries and
stability of galenics
stored for months
under different
conditions of
temperature and
relative humidity**

Croat Med J. 2012;
53: 173-184


CAMEROUN 2012



PHARMACEUTICAL FORMS TESTS (Ph Eur)

- Uniformity of content (2.9.6)
- Uniformity of mass (2.9.5)
- Disintegration (2.9.1)
- Friability (2.9.7)
- Hardness (2.9.8)
- Sterility (2.6.1)

CAMEROUN 2013



CAMEROUN 2013



- Population: 20 million
- Pharmacies on the national territory: 331
- Yaoundé+Douala: 81 pharmacies

**HOW MANY ARE THE
STREET VENDORS?**

PRELIMINARY RESULTS:

- 1047 FAMILIES LIVING IN YAOUNDÉ: THE 99.6%, EVEN IF **SCHOOLED**, BUY MEDICINAL PRODUCTS BY STREET VENDORS
- THE 34% OF SUBJECTS IS **AWARE OF THE RISKS**. THE 60% BUY THESE PRODUCTS DUE TO **FINANCIAL DIFFICULTIES**
- 74 STREET VENDORS HAVE BEEN INTERVIEWED: THE 80% IS **MEDIUM-HIGH CULTURAL GRADE**



A.P.P.A.® PROJECT

**PLANNING, CARRYING OUT, STARTING LABS IN ORDER TO PREPARE GALENIC
MEDICINAL PRODUCTS AND RELATIVE QUALITY CONTROL IN DEVELOPING
COUNTRIES**

With the patronage of:



Università degli Studi di Torino

and



FEDERAZIONE ORDINI
FARMACISTI ITALIANI



ORDINE DEI FARMACISTI
PROVINCIA DI TORINO



federfarma piemonte

www.progettoappa.it

appa.onlus@unito.it

PHASES OF *A.P.P.A.*[®] PROJECT



Phase «zero»

Preliminary pharmaco-economic study which implies a trip of the *A.P.P.A.*[®] staff on site to value the local situation and recipient areas. Some medicines should be purchased in local pharmacies and sent to the laboratory of the University of Turin to value if these medicinal products, present on the local market, respect the declared characteristics or are counterfeit.

1

Choice of the place where building the galenic lab, choice of medicines needed and of the correct pharmaceutical forms, related to the local pathologies.

2

Stage in *A.P.P.A.*[®] lab of Turin, for a Pharmacy's student of Pharmacy Faculty of Turin; the stage leads to learn all the necessary to be able to prepare the programmed medicinal products.

3

A technician of the Country holding the lab comes to Italy to learn the procedures of galenic medicines in *A.P.P.A.*[®] lab of Turin, under a Pharmacy's student supervision. During this period the material needed for galenic lab will be sent to local partners.

4

Training period in the chosen Country, during which the local technician, who has been in Italy to learn galenic methods and procedures, will be coordinated in his work by the Pharmacy's student sent to the *A.P.P.A.*[®] lab .

5

Quality control of medicinal products routinely prepared in new galenic lab; moreover some sample of these are sent to University of Turin, Pharmacy Faculty, where they are tested to verify their quality.

6

Periodical stages at new lab for Pharmacy's students of Pharmacy Faculty of Turin are performed each year both to give a continuous supervision of medicinal products prepared in the lab and to create new formulations according to the requests of medical doctors responsible of the medical centers.


WHY GALENICS IN DC?

USING LOCAL PERSONAL TEACHING THEM A JOB:
AUTONOMY

ALLOWING THE SALE OF CHEAP HIGH QUALITY
MEDICINES

AVOIDING THE PURCHASE OF MEDICINES
ILLEGALLY IMPORTED

CUSTOMIZING THE DOSAGES AND
PHARMACEUTICAL FORMS ACCORDING TO THE
ACTUAL NEEDS OF PATIENTS



BASIC CONDITIONS FOR OPENING **A LAB FOR THE PREPARATION OF GALENIC MEDICINAL PRODUCTS**

- **HIGH PERCENTAGE OF COUNTERFEIT MEDICINES IN THE AREA**
- **LOCAL POOR AVAILABILITY OF QUALITY MEDICINES**
- **HIGH COST OF INDUSTRIAL MEDICINES**
- **APPROVAL OF LOCAL AUTHORITIES**

AIM

The project was born from the need and the desire to teach a trade to people leaving in Developing Countries and to ensure the production of safe and effective medicines

EASIER ACCESS TO MEDICINES



DECREASE MORTALITY

AFRICA: HIGH PRESENTS OF
COUNTERFEIT MEDICINES



NO THERAPEUTIC
EFFECT



CASES OF
INTOXICATION


ENDEMIC DESEASES IN THE AREA

- MALARIA
- SALMONELLA
- VENEREAL DESEASES
- HEPATITIS A,B,C,D,E,
- HIV
- TUBERCULOSIS
- OTHERS

CHOICE OF THERAPEUTIC CLASSES FOR THE GALENIC LAB

- ANTIMALARALS
- TOPICAL ANTIFUNGAL
- TOPICAL AND SYSTEMIC ANTIBIOTICS
- SYSTEMIC AND TOPICAL NSAD
- ANTIPYRETICS
- ANTIPARASITICS (antihelmintics, antiamoebic, scabidicid)
- DISINFECTANTS

FORMULATION



PHARMACEUTICAL FORM



OINTMENT FOR SKIN
APPLICATION



LIQUID
• ORAL
• FOR SKIN
APPLICATION



SUPPOSITORY



ORAL SOLID

INDICE

PREP. SEMISOLIDE PER APPLICAZIONE CUTANEA	CAM 1	CAM 2	HAITI	TCHAD	MAD 1	MAD 2	ANG 1	ANG 2
ac. salicilico - ac. benzoico				X*				
aciclovir crema		X		X*	X	X		

amrica gel								
betametazone crema					X			
cloridina crema							X	X
econazolo crema							X	
gel antiemorroidario							X	
idrocortisone crema							X	
iodopovidone unguento							X	
iodopovidone con glucosio unguento							X	
ketoprofene gel							X	
lidocaina gel					X			
neomicina solfato crema							X	
neomicina-idrocortisone-prometazina crema					X	X	X	X
prometazina crema							X	
zinco ossido pasta							X	

PREP. LIQUIDE PER APPLICAZIONE CUTANEA
cloridina soluzione disinfettante
cloridina collutorio
iodopovidone soluzione cutanea (betadine)
ipoclorito di sodio
sapone disinfettante
sospensione di benzile benzoato
soluzione di perossido di idrogeno

PREPARAZIONI SOLIDE

acido acetilsalicilico
acido ascorbico
acido folico
aminofillina
amoxicillina
bisacodile
captopril

PREPARAZIONI LIQUIDE AD USO ORALE

SOLUZIONI

captopril
furosemide

SOSPENSIONI

amoxicillina
carbocisteina

cloramfenicolo
eritromicina
magnesio e alluminio idrossido
metronidazolo
vitamina B complex

SCIROPPI

CAM 1

acido ascorbico
carbonato di potassio
carbocisteina
chinina
fero solfato-vitamina C
glicerolo
ibuprofene
paracetamolo
paracetamolo pediatrico
propanololo
ranitidina
salbutamolo
vitamina B6
vitamina B12-ac.folico

GOCCE

CAM 1

chinina
nifedipina
ranitidina
salbutamolo
vitamina B6

ALTRE

CAM 1

lassativo orale

GEL ORALI	CAM 1	CAM 2	HAITI	TCHAD	MAD 1	MAD 2	ANG 1	ANG 2
cloridina				X				
lidocaina				X*	X	X		

POLVERI PER USO ORALE	CAM 1	CAM 2	HAITI	TCHAD	MAD 1	MAD 2	ANG 1	ANG 2
chinina								
ibuprofene								
mebendazolo								

PREPARAZIONI RETTALI	CAM 1	CAM 2	HAITI	TCHAD	MAD 1	MAD 2	ANG 1	ANG 2
paracetamolo supposte								X

PREPARAZIONI STERILI	CAM 1	CAM 2	HAITI	TCHAD	MAD 1	MAD 2	ANG 1	ANG 2
sodio cloruro 0,9% 10 ml gtt nasali			X					
sodio cloruro 0,9% 500 ml i.v.				X				
glucosio 5% 500 ml i.v.				X				
ringer lattato 500 ml i.v.				X				

* preparazioni sospese a periodi alterni in base alle necessità dell'ospedale.

A.P.P.A.® LABS HANDBOOK

SEMISOLID PREPARATIONS FOR CUTANEOUS APPLICATION

LIQUID PREPARATIONS FOR CUTANEOUS APPLICATION

SOLID PREPARATIONS

LIQUID PREPARATIONS FOR ORAL USE

Solutions

Suspension

Syrups

Drops

ORAL GEL

POWDER FOR ORAL USE

RECTAL PREPARATIONS

STERILE PREPARATIONS

Large volume parenteral solutions

101

FORMULATIONS

SAINT DAMIEN PAEDIATRIC HOSPITAL PORT-AU-PRINCE - HAITI



HAITI: WHY?

MEDICINAL PRODUCTS

LOT	API	PROVENANCE	RESULTS
6C090	Acetazolamide 250 mg	Haiti	Unsatisfied: Uniformity of content (2.9.6), Friability (2.9.7)
0302609	Ampicillin 1g	India	Unsatisfied: Bacterial endotoxins (2.6.14.)
071202	Chloramphenicol 1g	USA	Suitable
09K4840 A	Phenobarbital 30 mg	Haiti	Unsatisfied: Friability (2.9.7), Hardness (2.9.8)
08E2978-A	Phenobarbital syrup 18mg/5ml	Haiti	Suitable
08111487	Propanolol 40mg	Brasil	Unsatisfied: Uniformity of content (2.9.6)
L08111487	Spironolactone 25mg	Domenican Republic	Suitable

PAEDIATRICS: WHY?

PREPARATION OF CAPSULES FOR CHILDREN FROM INDUSTRIAL HIGH-DOSE TABLETS



PROBLEMS:

- ✓ Method of preparation
- ✓ Quality of industrial tablets
- ✓ Stability of the preparations
- ✓ Administration of capsules for the neonatal and paediatric treatment

CAPSULES PRODUCED IN 2010

LOT	API	PROVENANCE	RESULTS
200910-A	Acetazolamide 25 mg	St Damien Hospital	Unsatisfied: Uniformity of content (2.9.6)
A-200S10-A	Acetazolamide 25 mg	St Damien Hospital	Suitable
121110-B Exp	Captopril 1,25 mg	St Damien Hospital	Unsatisfied: Uniformity of mass (2.9.5)
230610-C	Phenytoin 10 mg	St Damien Hospital	Suitable
230610-G	Phenytoin 10 mg	St Damien Hospital	Suitable

A.P.P.A.[®] GALENIC LAB IN HAITI: SAINT DAMIEN PAEDIATRIC HOSPITAL

STUDY AND FORMULATION OF ORAL LIQUID PAEDIATRIC FORMULATIONS: METHODOLOGICAL APPROACH



- ✓ In agreement with local medical doctors the **drugs** for the paediatric therapy are **chosen** and then **formulated**: **liquid oral** formulations are preferred and appropriate excipients are selected.
- ✓ For each formulation a **specific card** (written in **local language**) has been prepared. The card shows the procedure of preparation and the characteristics of each component present in the formulation.
- ✓ Each preparation has been tested to check its **quality** and its **stability** under different environmental conditions in accordance with the EMA guidelines.

PREPARATIONS PEDIATRIQUES

SIROPS

ACIDE ASCORBIQUE 10 mg/ml
CANREONATE DE POTASSIUM 1 mg/ml
FER SULFATE 5 mg/ml
IBUPROFENE 20 mg/ml
PROPANOLOL 0,5 mg/ml
RANITIDINE 15 mg/ml
SALBUTAMOL 0,4 mg/ml
VITAMINE B ₆ 1 mg/ ml

SOLUTIONS

CAPTOPRIL 1 mg/ml
FUROSEMIDE 1 mg/ml

GOUTTES

NIFEDIPINE 1 mg/gtt
RANITIDINE 4 mg/gtt
SALBUTAMOL 0,2 mg/gtt
VITAMINE B6 0,5 mg/gtt

SUSPENSIONS

VITAMINE B COMPLEX 5,8 mg/ml
MAGNESIUM ET ALUMINIUM HYDROXYDE 200 mg/ml



PROPANOLOL CHLORHYDRATE SIROP 0,5 mg/ml

Formulation pour 100 ml:

Propanolol chlorhydrate	0,05 g
Carboxyméthylcellulose sodique	1,00 g
Sodium citrate	0,21 g
Acide citrique monohydraté	0,28 g
Eau dépurée	72,28 g
Nipagine sodique	0,07 g
Saccharose sirop	32,23 g

Caractéristiques chimiques-physiques:

Poudre cristalline blanche ou blanchâtre, il est inodore et avec un goût amer.
Soluble dans l'eau (1:20) et dans l'alcool (1:20).
p.f. = 163-166 °C.

Propriétés pharmacologiques:

Le propranolol a activité β -bloquant, il est un antagoniste compétitif des deux récepteurs β_1 et β_2 , non cardiosélectif.
Il est utilisé dans l'hypertension.

Posologie pédiatrique:

2,5-5mg correspondant à 5-10 ml.

Préparation:

1. Solubiliser la nipagine sodique dans l'eau dépurée.
2. Ajouter le sodium citrate et l'acide citrique monohydraté dans la solution.
3. Ajouter le propranolol chlorhydrate.
4. Ajouter la carboximéthylcellulose sodique peu à la fois, mélanger très lentement.
5. Ajouter le saccharose sirop.
6. Contrôler le pH. (il ne doit pas être supérieur à 4,5).

Instructions et contre-indication:

Contre-indiqué pour les patients avec des maladies obstructives chroniques des voies aériennes.

Stabilité et conservation de propranolol:

Conserver dans des récipients bien fermés, à l'abri de la lumière et de l'air.



Saint Damien Hospital

STABILITY STUDY OF THE PREPARED LIQUID PHARMACEUTICAL FORMS

Method:

STORAGE CONDITION	T (°C)	RH	PERIOD COVERED BY DATA	ANALYTICAL METHOD
<i>Standard</i>	25±2	60±5%	12 months, analysis at time zero (T0) and every 30 days (from TS-1 to TS-12)	UV-VIS spectrophotometric assay
<i>Refrigerator</i>	5±3	-	12 months, analysis at time zero (T0) and every 30 days (from TR-1 to TR-12)	
<i>Accelerated</i>	40±2	60±5%	3 months, analysis at time zero (T0) and every 30 days (from TA-1 through TA-3)	

EMA Guideline on stability testing: stability testing of existing active substances and related finished products, 2003, CPMP/QWP/122/02, rev 1 corr




EVALUATION OF THE EXPIRATION DATE

STABILITY STUDY: RESULTS

PREPARATIONS PEDIATRIQUES	
SIROPS	ACIDE ASCORBIQUE 10 mg/ml
	CANREONATE DE POTASSIUM 1 mg/ml
	FER SULFATE 5 mg/ml
	IBUPROFENE 20 mg/ml
	PROPANOLOL 0,5 mg/ml
	RANITIDINE 15 mg/ml
	SALBUTAMOL 0,4 mg/ml
	VITAMINE B ₆ 1 mg/ml
SOLUTIONS	CAPTOPRIL 1 mg/ml
	FUROSEMIDE 1 mg/ml
GOUTTES	NIFEDIPINE 1 mg/gtt
	RANITIDINE 4 mg/gtt
	SALBUTAMOL 0,2 mg/gtt
	VITAMINE B ₆ 0,5 mg/gtt
SUSPENSIONS	VITAMINE B COMPLEX 5,8 mg/ml
	MAGNESIUM ET ALUMINIUM HYDROXYDE 200 mg/ml

The stability has been demonstrated for **12 MONTHS** for **all formulations**



BUT **housing** and **environmental** conditions are **not suitable** for a proper storage of the preparations



VALIDITY PERIOD:
3 MONTHS

PAEDIATRIC FORMULATIONS: NON ONLY IN HAITI

EXTEMPORANEOUS SUSPENSION FOR ORAL USE



Total amount of solvent
each notch = 1 dosage unit

CAMEROUN



SUPPOSITORY



ANGOLA



QUALITY CONTROL AND QUALITY ASSURANCE

Galenics, in accord with the European Law (Ph Eur), must guarantee "the quality as a fundamental support to the security and the efficacy"

D.C.

PHARMACEUTICAL FORMS TESTS

Ointments for skin application; Suppositories:

- Verify of accuracy of followed procedures
- Control of aspect
- Control of the amount to sell
- Control of the solidity of packing

Stiff capsules:

- Verify the accuracy of followed procedures
- Control of aspect and solidity of capsules
- Control of the number of capsules prepared
- Mass uniformity of capsules

Liquid medicinal products:

- Verify the accuracy of followed procedures
- Control of the amount of product to sell
- Control of the solidity of packing

RAW MATERIALS: Organoleptic control
Melting point

ITALY

STABILITY TESTS
(EMA)

PHARMACEUTICAL FORMS TESTS (Ph Eur)
Uniformity of content (2.9.6)
Uniformity of mass (2.9.5)
Disintegration (2.9.1)
Friability (2.9.7)
Hardness (2.9.8)
Sterility (2.6.1)

QUALITY CONTROL AND QUALITY ASSURANCE

ANALYSIS	METHOD REF.	ACCEPTANCE CRITERIA
General aspect	Visual	Posological unit integrity
Uniformity of content	Ph. Eur. 7 ed. Assay 2.9.6	Each individual content is between 85% and 115% of the average content (10 dosage units)



SPECTOPHOTOMETRY UV/VIS




STANDARDIZATION OF RESULTS
LOW COSTS
SIMPLE EXECUTION

*"...reuse, repair equipment and goods instead of throwing them in a landfill, **exceeding the consumerist obsession of the obsolescence of objects** and the tension to the new..."*

A. Salza "Niente. Come si vive quando manca tutto. Antropologia della povertà estrema", Sperling & Kupfer 2009

A.P.P.A.® LABS IN THE WORLD



ANGOLA – Cubal, Nossa Senhora de Paz hospital, Companhia de Santa Teresa de Jesus.

ANGOLA – Funda, A.M.E.N. ONG health care facility.

CAMEROUN – Douala, La Bethanie hospital.

CAMEROUN – Garoua, Notre Dame des Apôtres hospital, Djamboutou.

CIAD – N'Djamena, Le Bon Samaritain hospital.

HAITI – Tabarre Chateaublond, N.P.H. Saint Damien paediatric hospital.

MADAGASCAR – Vohipeno, Henintsoa hospital.

MADAGASCAR – Ihoso, Eglise Catholique Apostolique Romaine medical center.



A.P.P.A.[®] 2005-2013

8 GALENICS LABS IN DEVELOPING COUNTRIES

ECONOMIC INVESTMENT IN RAW MATERIALS: \approx 100.000 €

***ADMINISTERED DOSES:
i.e. cps \approx 7.500.000***



**A GOOD REASON TO GO ON
BUT WITH THE AIM OF
BECOME LESS AND LESS INDISPENSABLES**